Michael Okunewitch
Stock Analyst at Maxim Group
(0.45)
# 3,814
Out of 4,681 analysts
19
Total ratings
16.67%
Success rate
-12.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTOR Citius Oncology | Initiates: Buy | $3 | $1.02 | +194.12% | 1 | Nov 27, 2024 | |
| OCGN Ocugen | Initiates: Buy | $4 | $0.94 | +323.82% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $2.71 | +342.80% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $2.06 | +191.26% | 2 | Aug 27, 2024 | |
| CMMB Chemomab Therapeutics | Initiates: Buy | $4 | $1.79 | +123.46% | 1 | May 13, 2024 | |
| LEXX Lexaria Bioscience | Maintains: Buy | $3 → $12 | $2.24 | +435.71% | 2 | Mar 5, 2024 | |
| ACRV Acrivon Therapeutics | Initiates: Buy | $24 | $7.44 | +222.58% | 1 | Oct 5, 2023 | |
| ANEB Anebulo Pharmaceuticals | Initiates: Buy | $6 | $1.44 | +316.67% | 1 | Sep 21, 2023 | |
| KPRX Kiora Pharmaceuticals | Maintains: Buy | $108 → $18 | $3.44 | +423.24% | 3 | Aug 9, 2023 | |
| ALZN Alzamend Neuro | Initiates: Buy | $225 | $1.25 | +17,900.00% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $18.10 | +38.16% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.50 | +300.00% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $0.51 | +684.47% | 1 | Mar 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.69 | +1,379.29% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $3.22 | +24.22% | 1 | Nov 30, 2021 |
Citius Oncology
Nov 27, 2024
Initiates: Buy
Price Target: $3
Current: $1.02
Upside: +194.12%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $0.94
Upside: +323.82%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $2.71
Upside: +342.80%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $2.06
Upside: +191.26%
Chemomab Therapeutics
May 13, 2024
Initiates: Buy
Price Target: $4
Current: $1.79
Upside: +123.46%
Lexaria Bioscience
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $2.24
Upside: +435.71%
Acrivon Therapeutics
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $7.44
Upside: +222.58%
Anebulo Pharmaceuticals
Sep 21, 2023
Initiates: Buy
Price Target: $6
Current: $1.44
Upside: +316.67%
Kiora Pharmaceuticals
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $3.44
Upside: +423.24%
Alzamend Neuro
Apr 12, 2023
Initiates: Buy
Price Target: $225
Current: $1.25
Upside: +17,900.00%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $18.10
Upside: +38.16%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.50
Upside: +300.00%
Mar 24, 2022
Initiates: Buy
Price Target: $4
Current: $0.51
Upside: +684.47%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $1.69
Upside: +1,379.29%
Nov 30, 2021
Initiates: Buy
Price Target: $4
Current: $3.22
Upside: +24.22%